The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Progress and Prospects on Vaccine Development against SARS-CoV-2
Open accessAbstract
In December 2019, the outbreak of pneumonia caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a serious pandemic in China and other countries worldwide. So far, more than 460,000 confirmed cases were diagnosed in nearly 190 countries, causing globally over 20,000 deaths. Currently, the epidemic is still spreading and there is no effective means to prevent the infection. Vaccines are proved to be the most effective and economical means to prevent and control infectious diseases. Several countries, companies, and institutions announced their programs and progress on vaccine development against the virus. While most of the vaccines are under design and preparation, there are some that have entered efficacy evaluation in animals and initial clinical trials. This review mainly focused on the progress and our prospects on field of vaccine development against SARS-CoV-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Self-citationA novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897 · cited 3×
“First, it is surface exposure and thus is able to be directly recognized by host immune system [11].”
BackgroundStructure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
Guo (2020) · doi:10.1186/s40779-020-00240-0 · Cited by 4,735
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · cited 1×
“mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, short production cycles, low-cost manufacturing, and safe administration [46].”
BackgroundHui, D. S., I Azhar, E., Madani, T. A., Ntoumi, F., Kock, R., Dar, O., Ippolito, G., Mchugh, T. D., Memish, Z. A., Drosten, C., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.01.009 · Cited by 3,809
Structure, Function, and Evolution of Coronavirus Spike Proteins
Li, F. (2016) · Annual Review of Virology · doi:10.1146/annurev-virology-110615-042301 · Cited by 2,740
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
On the origin and continuing evolution of SARS-CoV-2
Tang, X., Wu, C., Li, X., Song, Y., Yao, X., Wu, X., Duan, Y., Zhang, H., Wang, Y., Qian, Z., et al. (2020) · National Science Review · doi:10.1093/nsr/nwaa036 · Cited by 1,616
Ahmed, S. F., Quadeer, A. A., & McKay, M. R. (2020) · Viruses · doi:10.3390/v12030254 · Cited by 1,116
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707304114 · Cited by 1,073 · cited 1×
“[19] demonstrated that higher titer of neutralizing antibodies in BALB/c mice immunized with recombinant prefusion MERS-CoV S protein.”
BackgroundThe Coronavirus Nucleocapsid Is a Multifunctional Protein
McBride, R., Van Zyl, M., & Fielding, B. (2014) · Viruses · doi:10.3390/v6082991 · Cited by 942
A structural analysis of M protein in coronavirus assembly and morphology
Neuman, B. W., Kiss, G., Kunding, A. H., Bhella, D., Baksh, M. F., Connelly, S., Droese, B., Klaus, J. P., Makino, S., Sawicki, S. G., et al. (2011) · Journal of Structural Biology · doi:10.1016/j.jsb.2010.11.021 · Cited by 841
Liu, L., Wei, Q., Lin, Q., Fang, J., Wang, H., Kwok, H., Tang, H., Nishiura, K., Peng, J., Tan, Z., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123158 · Cited by 830 · cited 1×
“Previous studies have demonstrated that full-length S protein can cause severe liver damage and may result in enhanced infection [14], which was defined as antibody-dependent enhancement (ADE) [65], and this effect may be probably caused by S protein specific antibodies [66,67].”
BackgroundNieto-Torres, J. L., DeDiego, M. L., Verdiá-Báguena, C., Jimenez-Guardeño, J. M., Regla-Nava, J. A., Fernandez-Delgado, R., Castaño-Rodriguez, C., Alcaraz, A., Torres, J., Aguilella, V. M., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004077 · Cited by 559
Adjuvant system AS01: helping to overcome the challenges of modern vaccines
Didierlaurent, A. M., Laupèze, B., Di Pasquale, A., Hergli, N., Collignon, C., & Garçon, N. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2016.1213632 · Cited by 516
Live attenuated vaccines: Historical successes and current challenges
Minor, P. D. (2015) · Virology · doi:10.1016/j.virol.2015.03.032 · Cited by 495
Mechanism of Immunopotentiation and Safety of Aluminum Adjuvants
HogenEsch, H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00406 · Cited by 430
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies
Liu, M. A. (2019) · Vaccines · doi:10.3390/vaccines7020037 · Cited by 427
He, Y., Zhou, Y., Liu, S., Kou, Z., Li, W., Farzan, M., & Jiang, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.09.106 · Cited by 403
Buchholz, U. J., Bukreyev, A., Yang, L., Lamirande, E. W., Murphy, B. R., Subbarao, K., & Collins, P. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403492101 · Cited by 385
Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
Petrovsky, N. (2015) · Drug Safety · doi:10.1007/s40264-015-0350-4 · Cited by 366
Saponins as vaccine adjuvants.
Kensil, C. R. (1996) · PubMed · Cited by 350
Garçon, N., Vaughn, D. W., & Didierlaurent, A. M. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.192 · Cited by 347
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Garçon, N., & Van Mechelen, M. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.29 · Cited by 314
Wang, Q., Zhang, L., Kuwahara, K., Li, L., Liu, Z., Li, T., Zhu, H., Liu, J., Xu, Y., Xie, J., et al. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00006 · Cited by 304
Novel coronavirus: From discovery to clinical diagnostics
Phan, T. (2020) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2020.104211 · Cited by 294
Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice
Coleman, C. M., Liu, Y. V., Mu, H., Taylor, J. K., Massare, M., Flyer, D. C., Glenn, G. M., Smith, G. E., & Frieman, M. B. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.04.016 · Cited by 293
Potential impact of seasonal forcing on a SARS-CoV-2 pandemic
Neher, R. A., Dyrdak, R., Druelle, V., Hodcroft, E. B., & Albert, J. (2020) · Swiss Medical Weekly · doi:10.4414/smw.2020.20224 · Cited by 286
Ahmed, S. F., Quadeer, A. A., & McKay, M. R. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.03.933226 · Cited by 256
Muthumani, K., Falzarano, D., Reuschel, E. L., Tingey, C., Flingai, S., Villarreal, D. O., Wise, M., Patel, A., Izmirly, A., Aljuaid, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac7462 · Cited by 251
Recent progress in adjuvant discovery for peptide-based subunit vaccines
Azmi, F., Ahmad Fuaad, A. A. H., Skwarczynski, M., & Toth, I. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.27332 · Cited by 239
Jiang, S., He, Y., & Liu, S. (2005) · Emerging Infectious Diseases · doi:10.3201/1107.050219 · Cited by 215
Leung, D. T. M., Tam, F. C. H., Ma, C. H., Chan, P. K. S., Cheung, J. L. K., Niu, H., Tam, J. S. L., & Lim, P. L. (2004) · The Journal of Infectious Diseases · doi:10.1086/422040 · Cited by 212
Cytotoxic T lymphocytes are critical in the control of infectious bronchitis virus in poultry
Collisson, E. (2000) · Developmental & Comparative Immunology · doi:10.1016/s0145-305x(99)00072-5 · Cited by 210
Comparison of DNA and mRNA vaccines against cancer
Jahanafrooz, Z., Baradaran, B., Mosafer, J., Hashemzaei, M., Rezaei, T., Mokhtarzadeh, A., & Hamblin, M. R. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.003 · Cited by 202
Promkuntod, N., van Eijndhoven, R. E. W., de Vrieze, G., Gröne, A., & Verheije, M. H. (2014) · Virology · doi:10.1016/j.virol.2013.09.018 · Cited by 197
Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees
Jiang, S. (2020) · Nature · doi:10.1038/d41586-020-00751-9 · Cited by 174 · cited 1×
“Safety is the most important issue that should be taken into consideration during drug and vaccine development, and some scientists urge that we should not rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees [64].”
BackgroundKim, T. W., Lee, J. H., Hung, C.-F., Peng, S., Roden, R., Wang, M.-C., Viscidi, R., Tsai, Y.-C., He, L., Chen, P.-J., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.9.4638-4645.2004 · Cited by 173
Liu, J., Sun, Y., Qi, J., Chu, F., Wu, H., Gao, F., Li, T., Yan, J., & Gao, G. F. (2010) · The Journal of Infectious Diseases · doi:10.1086/656315 · Cited by 168
Krempl, C., Schultze, B., Laude, H., & Herrler, G. (1997) · Journal of Virology · doi:10.1128/jvi.71.4.3285-3287.1997 · Cited by 167
Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes
Temperton, N. J., Chan, P. K. S., Simmons, G., Zambon, M. C. F. A., Tedder, R. S., Takeuchi, Y., & Weiss, R. A. (2005) · Emerging infectious diseases · doi:10.3201/eid1103.040906 · Cited by 157
A sensitive retroviral pseudotype assay for influenza H5N1‐neutralizing antibodies
Temperton, N. J., Höschler, K., Major, D., Nicolson, C., Manvell, R. J., Hien, V. M., Ha, D. Q., de Jong, M. D., Zambon, M. C. F. A., Takeuchi, Y., et al. (2007) · Influenza and Other Respiratory Viruses · doi:10.1111/j.1750-2659.2007.00016.x · Cited by 142
Recent developments for Pseudomonas vaccines
Sharma, A., Krause, A., & Worgall, S. (2011) · Human Vaccines · doi:10.4161/hv.7.10.16369 · Cited by 137
Prospects for a MERS-CoV spike vaccine
Zhou, Y., Jiang, S., & Du, L. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1506702 · Cited by 136
Lan, J., Yao, Y., Deng, Y. L., Chen, H., Lu, G., Wang, W., Bao, L., Deng, W., Wei, Q., Gao, G. F., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.08.031 · Cited by 111
The economic value of vaccination: why prevention is wealth
Rémy, V., Largeron, N., Quilici, S., & Carroll, S. (2015) · Journal of Market Access & Health Policy · doi:10.3402/jmahp.v3.29284 · Cited by 108
Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults
Tsai, T. F. (2013) · Infection & Chemotherapy · doi:10.3947/ic.2013.45.2.159 · Cited by 107
Liu, H., Su, D., Zhang, J., Ge, S., Li, Y., Wang, F., Gravel, M., Roulston, A., Qin, S., Xu, W. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09518-1 · Cited by 97
Self-citationAdney, D. R., Wang, L., van Doremalen, N., Shi, W., Zhang, Y., Kong, W., Miller, M. R., Bushmaker, T., Scott, D. P., de Wit, E., et al. (2019) · Viruses · doi:10.3390/v11030212 · Cited by 88
Pang, H., Yinggang, L., Xue-qing, H., Xu, Y., Jiang, F., Wu, D., Kong, X., Bartlam, M. G., & Rao, Z. (2004) · Journal of General Virology · doi:10.1099/vir.0.80111-0 · Cited by 87
Seo, S. H., Pei, J., Briles, W. E., Dzielawa, J. A., & Collisson, E. W. (2000) · Virology · doi:10.1006/viro.2000.0211 · Cited by 85
Jiaming, L., Yanfeng, Y., Deng, Y. L., Yawei, H., Linlin, B., Baoying, H., Jinghua, Y., Gao, G. F., Chuan, Q., & Wenjie, T. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.11.064 · Cited by 84
Ontiveros, E., Kim, T. S., Gallagher, T. M., & Perlman, S. M. (2003) · Journal of Virology · doi:10.1128/jvi.77.19.10260-10269.2003 · Cited by 82
Artificial Molecular Clamp: A Novel Device for Synthetic Polymerases
Takashima, Y., Osaki, M., Ishimaru, Y., Yamaguchi, H., & Harada, A. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201102834 · Cited by 82
Luo, F., Liao, F., Wang, H., Tang, H.-B., Yang, Z.-Q., & Hou, W. (2018) · Virologica Sinica · doi:10.1007/s12250-018-0009-2 · Cited by 82
Chen, Y., Lu, S., Jia, H., Deng, Y., Zhou, J., Huang, B., Yu, Y., Lan, J., Wang, W., Lou, Y., et al. (2017) · Emerging Microbes & Infections · doi:10.1038/emi.2017.50 · Cited by 81
Receptor-binding domain as a target for developing SARS vaccines.
Zhu, X., Liu, Q., Du, L., Lu, L., & Jiang, S. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2013.06.06 · Cited by 80
Zakhartchouk, A. N., Sharon, C., Satkunarajah, M., Aupérin, T. C., Viswanathan, S., Mutwiri, G., Petric, M., See, R. H., Brunham, R. C., Finlay, B. B., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.084 · Cited by 79
The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic MicePreprint
Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., Wei, Q., Yu, P., Xu, Y., Qi, F., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.07.939389 · Cited by 79
Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen
Nyon, M. P., Du, L., Tseng, C.-T. K., Seid, C. A., Pollet, J. B. K., Naceanceno, K. S., Agrawal, A. S., Algaissi, A. A., Peng, B., Tai, W., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.02.065 · Cited by 69
Development and performance of inactivated vaccines against foot and mouth disease
Barteling, S. J. (2002) · Scientific and Technical Review (World Organisation for Animal Health) · doi:10.20506/rst.21.3.1361 · Cited by 66
Live attenuated tularemia vaccines: Recent developments and future goals
Marohn, M. E., & Barry, E. M. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.096 · Cited by 61
Woo, P. C. Y., Lau, S. K. P., Tsoi, H.-W., Chen, Z., Wong, B. H. L., Zhang, L., Chan, J. K. H., Wong, L.-P., He, W., Ma, C., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.05.023 · Cited by 58
Wang, Y., Tai, W., Yang, J., Zhao, G., Sun, S., Tseng, C.-T. K., Jiang, S., Zhou, Y., Du, L., & Gao, J. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1296994 · Cited by 56
A Fusion Peptide in the Spike Protein of MERS Coronavirus
Alsaadi, E. A. J., Neuman, B. W., & Jones, I. M. (2019) · Viruses · doi:10.3390/v11090825 · Cited by 39
The Economic Value of Vaccination: Why Prevention Is Wealth
Remy, V. F. M., Largeron, N., Quilici, S., & Carroll, S. (2014) · Value in Health · doi:10.1016/j.jval.2014.08.1211 · Cited by 21
Virus-like particles in picornavirus vaccine development
Dong, H., Guo, H., & Sun, S. (2014) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-014-5639-1 · Cited by 20
Cited by
The SARS-CoV-2 main protease as drug target
Ullrich, S., & Nitsche, C. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127377 · Cited by 772
A systematic review of SARS-CoV-2 vaccine candidates
Dong, Y., Dai, T., Wei, Y., Zhang, L., Zheng, M., & Zhou, F. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00352-y · Cited by 545
A Global Review on Short Peptides: Frontiers and Perspectives
Apostolopoulos, V., Bojarska, J., Chai, T.-T., Elnagdy, S., Kaczmarek, K., Matsoukas, J., New, R., Parang, K., Lopez, O. P., Parhiz, H., et al. (2021) · Molecules · doi:10.3390/molecules26020430 · Cited by 421
Duan, L., Zheng, Q., Zhang, H., Niu, Y., Lou, Y., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.576622 · Cited by 408
COVID-19 vaccines: The status and perspectives in delivery points of view
Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375
“Antigen selection for desired immune response Independent of the vaccination platform, selecting the most potent target antigen(s) is pivotal in the development of effective COVID-19 vaccines [214,215].”
Background
Metadata
- Authors
- Zhang, J., Zeng, H., Gu, J., Li, H., Zheng, L., & Zou, Q.
- Venue
- Vaccines
- Publisher
- MDPI AG
- Published
- 2020-03-29
- Volume
- 8
- Issue
- 2
- Pages
- 153
- ISSN
- 2076-393X (ISSN-L)
- OpenAlex
- W3013893246
- Cited by
- 282
- References
- 70
- FWCI
- 8.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.